TransMedics Group Inc vs UnitedHealth Group Inc — how do they compare? TransMedics Group Inc trades at $87.67 (market cap $3.02B), while UnitedHealth Group Inc trades at $405.54 (market cap $364.06B). The key difference: UnitedHealth Group Inc is far larger — about 120.5× TransMedics Group Inc's market cap, and UnitedHealth Group Inc pays a 2.29% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | UNH | |
|---|---|---|
Market Cap | $3.02B | $364.06B |
Sector | Technology | Health |
52-Week High | $150.42 | $436.35 |
52-Week Low | $61.99 | $259.02 |
Enterprise Value | $3.41B | $405.92B |
Dividend Yield | — | 2.29% |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
UnitedHealth Group (UNH) trades at $402.19, down 1.6% with bearish technical signals despite strong fundamental performance. The company reported three consecutive quarterly earnings beats with Q1 2026 EPS of $7.23 beating estimates by 12%. Revenue grew to $447.57 billion in 2025, though net margins compressed to 2.69%. Analyst consensus remains strongly bullish with 83% buy ratings and a $476.50 price target representing 18% upside potential.
UNH presents a compelling long-term investment opportunity driven by aging demographics and healthcare digitization, but faces near-term headwinds from regulatory scrutiny and margin pressure. The stock's current valuation at 25.85x P/E appears reasonable given growth prospects, though investors should monitor legal challenges and Medicare reimbursement trends that could impact profitability.
Trailing returns across standard periods
Latest headlines on both assets
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →